Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Operating Leases (2019 - 2025)

Historic Operating Leases for Summit Therapeutics (SMMT) over the last 7 years, with Q3 2025 value amounting to $2.7 million.

  • Summit Therapeutics' Operating Leases fell 3563.11% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 3563.11%. This contributed to the annual value of $3.5 million for FY2024, which is 495.44% up from last year.
  • According to the latest figures from Q3 2025, Summit Therapeutics' Operating Leases is $2.7 million, which was down 3563.11% from $2.4 million recorded in Q2 2025.
  • Over the past 5 years, Summit Therapeutics' Operating Leases peaked at $5.8 million during Q1 2024, and registered a low of $351000.0 during Q1 2021.
  • Over the past 5 years, Summit Therapeutics' median Operating Leases value was $2.8 million (recorded in 2022), while the average stood at $2.8 million.
  • Its Operating Leases has fluctuated over the past 5 years, first surged by 215466.67% in 2021, then tumbled by 5146.5% in 2025.
  • Over the past 5 years, Summit Therapeutics' Operating Leases (Quarter) stood at $1.7 million in 2021, then soared by 63.39% to $2.8 million in 2022, then increased by 19.07% to $3.3 million in 2023, then increased by 4.95% to $3.5 million in 2024, then decreased by 21.58% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.4 million for Q2 2025, and $2.9 million during Q1 2025.